BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin K. Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray-Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O'Malley, Setsuko K. Chambers, Scott H Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James X. Sun & 5 others Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

: A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity.This article is highlighted in the In This Issue feature, p. 151.

Original languageEnglish (US)
Pages (from-to)210-219
Number of pages10
JournalCancer discovery
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Platinum
Carcinoma
Mutation
DNA
Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
rucaparib
Disease-Free Survival
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. / Lin, Kevin K.; Harrell, Maria I.; Oza, Amit M.; Oaknin, Ana; Ray-Coquard, Isabelle; Tinker, Anna V.; Helman, Elena; Radke, Marc R.; Say, Carmen; Vo, Lan Thanh; Mann, Elaina; Isaacson, Jeffrey D.; Maloney, Lara; O'Malley, David M.; Chambers, Setsuko K.; Kaufmann, Scott H; Scott, Clare L.; Konecny, Gottfried E.; Coleman, Robert L.; Sun, James X.; Giordano, Heidi; Brenton, James D.; Harding, Thomas C.; McNeish, Iain A.; Swisher, Elizabeth M.

In: Cancer discovery, Vol. 9, No. 2, 01.02.2019, p. 210-219.

Research output: Contribution to journalArticle

Lin, KK, Harrell, MI, Oza, AM, Oaknin, A, Ray-Coquard, I, Tinker, AV, Helman, E, Radke, MR, Say, C, Vo, LT, Mann, E, Isaacson, JD, Maloney, L, O'Malley, DM, Chambers, SK, Kaufmann, SH, Scott, CL, Konecny, GE, Coleman, RL, Sun, JX, Giordano, H, Brenton, JD, Harding, TC, McNeish, IA & Swisher, EM 2019, 'BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma', Cancer discovery, vol. 9, no. 2, pp. 210-219. https://doi.org/10.1158/2159-8290.CD-18-0715
Lin, Kevin K. ; Harrell, Maria I. ; Oza, Amit M. ; Oaknin, Ana ; Ray-Coquard, Isabelle ; Tinker, Anna V. ; Helman, Elena ; Radke, Marc R. ; Say, Carmen ; Vo, Lan Thanh ; Mann, Elaina ; Isaacson, Jeffrey D. ; Maloney, Lara ; O'Malley, David M. ; Chambers, Setsuko K. ; Kaufmann, Scott H ; Scott, Clare L. ; Konecny, Gottfried E. ; Coleman, Robert L. ; Sun, James X. ; Giordano, Heidi ; Brenton, James D. ; Harding, Thomas C. ; McNeish, Iain A. ; Swisher, Elizabeth M. / BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. In: Cancer discovery. 2019 ; Vol. 9, No. 2. pp. 210-219.
@article{4ca22ec251164760ad45425adc2589ac,
title = "BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma",
abstract = ": A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18{\%} (2/11) of platinum-refractory and 13{\%} (5/38) of platinum-resistant cancers, compared with 2{\%} (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity.This article is highlighted in the In This Issue feature, p. 151.",
author = "Lin, {Kevin K.} and Harrell, {Maria I.} and Oza, {Amit M.} and Ana Oaknin and Isabelle Ray-Coquard and Tinker, {Anna V.} and Elena Helman and Radke, {Marc R.} and Carmen Say and Vo, {Lan Thanh} and Elaina Mann and Isaacson, {Jeffrey D.} and Lara Maloney and O'Malley, {David M.} and Chambers, {Setsuko K.} and Kaufmann, {Scott H} and Scott, {Clare L.} and Konecny, {Gottfried E.} and Coleman, {Robert L.} and Sun, {James X.} and Heidi Giordano and Brenton, {James D.} and Harding, {Thomas C.} and McNeish, {Iain A.} and Swisher, {Elizabeth M.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1158/2159-8290.CD-18-0715",
language = "English (US)",
volume = "9",
pages = "210--219",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

AU - Lin, Kevin K.

AU - Harrell, Maria I.

AU - Oza, Amit M.

AU - Oaknin, Ana

AU - Ray-Coquard, Isabelle

AU - Tinker, Anna V.

AU - Helman, Elena

AU - Radke, Marc R.

AU - Say, Carmen

AU - Vo, Lan Thanh

AU - Mann, Elaina

AU - Isaacson, Jeffrey D.

AU - Maloney, Lara

AU - O'Malley, David M.

AU - Chambers, Setsuko K.

AU - Kaufmann, Scott H

AU - Scott, Clare L.

AU - Konecny, Gottfried E.

AU - Coleman, Robert L.

AU - Sun, James X.

AU - Giordano, Heidi

AU - Brenton, James D.

AU - Harding, Thomas C.

AU - McNeish, Iain A.

AU - Swisher, Elizabeth M.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - : A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity.This article is highlighted in the In This Issue feature, p. 151.

AB - : A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity.This article is highlighted in the In This Issue feature, p. 151.

UR - http://www.scopus.com/inward/record.url?scp=85058972448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058972448&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-18-0715

DO - 10.1158/2159-8290.CD-18-0715

M3 - Article

VL - 9

SP - 210

EP - 219

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 2

ER -